A Cytokine Compass: IL-18 Levels Chart the Course of Still Disease
A new study in Arthritis & Rheumatology reveals that interleukin-18 (IL-18), a key pro-inflammatory cytokine, serves as a powerful biomarker for predicting disease trajectory in patients with Still disease. Researchers analyzed 66 biologic-naive patients receiving first-line interleukin-1 inhibitor (IL-1i) therapy. They found that baseline IL-18 levels above 45,000 pg/mL were strongly associated with active disease at 12 months, risk of developing macrophage activation syndrome (MAS) within 24 months, and a chronic-persistent disease course. Crucially, IL-18 levels measured just three months after treatment initiation proved to be an even more robust predictor. An IL-18 level exceeding 15,000 pg/mL at this three-month checkpoint was a potent independent predictor of a chronic-persistent trajectory, explaining a significant portion of the variance in outcomes. This research highlights the dynamic role of cytokine monitoring in autoimmune and autoinflammatory conditions.
Study Significance: This work provides a clear, actionable framework for immunologists and rheumatologists to move beyond reactive treatment. By identifying IL-18 as a quantifiable risk-stratification tool, it enables a shift towards precision medicine in managing complex autoinflammatory syndromes. Clinically, these findings support the early and serial measurement of specific cytokines to guide therapeutic decisions, potentially allowing for timely treatment escalation or adjustment to prevent severe complications like MAS and improve long-term patient outcomes.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
